ASML Delays Capacity Expansion, Stock Drops Despite Strong Q3

What happened

ASML reported strong third-quarter 2026 results, with revenue and net income growth outpacing prior trends, driven by higher-margin servicing revenue that now exceeds machine sales. The company guided for 20% sales growth and 48% net income growth for full-year 2026, reflecting robust demand for its lithography systems. However, management announced a delay in capacity expansion plans, pushing them until after fiscal 2027, which signals caution about whether AI-driven demand can sustain the previously planned 30% increases in EUV and DUV immersion output. This reversal contradicts earlier commitments and removes a key near-term catalyst that investors had priced into the stock's premium valuation. Consequently, shares dropped as the market reassessed the growth trajectory and execution risk.

Implication

The delay in capacity expansion until after FY2027 removes a key driver that was expected to convert strong demand into revenue growth, and it raises questions about either the durability of AI-related orders or ASML's ability to scale production efficiently. With the stock trading at approximately 59.4 times earnings and 46.8 times EV/EBITDA, the valuation already priced in flawless execution, leaving little margin for missed expectations or further push-outs. While the rising mix of servicing revenue is positive for margins and provides some resilience, it is unlikely to fully offset the loss of equipment-sale growth from delayed capacity. Investors should consider waiting for a re-rating toward the $1,550 attractive entry level or for concrete evidence that capacity expansion is back on track before adding positions. Key risks to monitor include China export controls, which could further pressure revenue mix, and any signs that customer fab readiness is slipping.

Thesis delta

The investment thesis shifts from a valuation-based WAIT to a more cautious WAIT/SELL bias because management's decision to delay capacity expansion until after FY2027 directly undermines the key growth catalyst that the market was pricing in. Previously, the plan was to increase EUV and DUV immersion capacity by 30% in 2027 to meet robust demand; the delay suggests either softer-than-expected order visibility or execution constraints, which raises the risk of revenue growth slowing. This increases the probability of the bear scenario, where the stock may drift toward the $1,450 implied value, and reduces confidence in the base case of $1,800.